IPO Inventory of Chinese biopharmaceutical companies in 2021

In 2021, a total of 89 Chinese biopharmaceutical companies (according to Shenwan Biopharmaceutical industry classification) will complete IPOs in mainland China, Hong Kong, and the United States

Among them, 57 were listed in mainland China (23 A-shares, 34 on the Science and Technology Innovation Board), raising 84.

(Data sourced from public information)

Among the 57 companies listed on the mainland, 35 are on the Shanghai Stock Exchange, including 34 on the Science and Technology Innovation Board and 1 on the Main Board; 18 on the Shenzhen Stock Exchange and 4 on the Beijing Stock Exchange

(Data sourced from public information)

Shanghai Stock Exchange (Science and Technology Innovation Board )

In 2021, a total of 34 Chinese biopharmaceutical companies will be listed on the Science and Technology Innovation Board, with a total IPO fundraising of about 57.

June was the month with the largest number of IPOs in a single month.

BeiGene, as the world's first Chinese biopharmaceutical company listed on the "US stock + H shares + A shares" three places, has become the biopharmaceutical company with the largest fundraising on the Science and Technology Innovation Board in 2021, with financing reaching 22.

Hong Kong Stock Exchange

In 2021, a total of 24 Chinese biopharmaceutical companies will go public in Hong Kong, raising a total of HK$56.

February was the month with the most fundraising in a single month, with a total of HK$13.

NASDAQ Exchange

In 2021, a total of 8 Chinese biopharmaceutical companies will be listed in the United States, all of which will be listed on the NASDAQ exchange, raising $1.

Liantuo Bio is the biopharmaceutical company that will raise the most funds from its IPO in the United States in 2021

(Data sourced from public information)

It can be seen that at present, the Science and Technology Innovation Board is the first choice for domestic biopharmaceutical companies to go public, and the enthusiasm for going to the United States has waned

Reference: 2021 Blue Book on China's Biopharmaceutical Investment and Financing